구조모아 (StructureMoa)항암 chemical structure spider web
방문프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | faricimab (Vabysmo, RG7716, faricimab-svoa) Roche / Genentech·Ang-2 / VEGF-A 53 trials·t½ Ocular ~7.5 days; minimal systemic exposure by design |
|---|---|
Overview Program | Vabysmo (faricimab) |
Overview Company | Roche / Genentech |
Overview Modality | ANTIBODY |
Overview Target | Ang-2 / VEGF-A |
Overview Indication | Wet AMD, diabetic macular edema, macular edema following retinal vein occlusion |
Overview Phase | APPROVED |
Overview Status | APPROVED |
Overview Content status | Curated Core |
Overview Data Confidence | Data Confidence · High |
Overview Development Signal | Development Signal · Established |
Overview Approval status | FDA approved |
Positioning Key differentiator | Dual pathway blockade targets vascular instability, not just leakage, which is what supports extended intervals. |
Positioning Known limitation | Persistent fluid despite dual blockade; interval shortening in a subset of eyes. |
Positioning Development positioning | Primary challenger to Eylea/Eylea HD on injection interval. |
MoA Mechanism | Neutralizes VEGF-A to reduce neovascularization and permeability while blocking Ang-2 to restore Tie2 signaling and vascular stability, reducing inflammation-driven leakage. |
MoA Biomarker | OCT central subfield thickness, BCVA, presence of intraretinal fluid. |
PK/PD Half-life | Ocular ~7.5 days; minimal systemic exposure by design |
PK/PD Species | Human, primate, CST reduction, fluid-free intervals, BCVA change |
PK/PD Animal (cat.) | Human |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Rat |
Toxicology Major finding | Injection-procedure risks — endophthalmitis, retinal detachment, IOP elevation — plus intraocular inflammation. Conjunctival hemorrhage is the most common local event. |
Toxicology CRS | N/A |
Clinical Safety signal | Injection-procedure risks — endophthalmitis, retinal detachment, IOP elevation — plus intraocular inflammation. Conjunctival hemorrhage is the most common local event. |
Clinical Selected reported efficacy | 16.9% |
Clinical Result source | ClinicalTrials.gov NCT04740905 |
Clinical Program phase | APPROVED |
Clinical Trial activity | No active/completed counts |
Clinical Trial ref | NCT04740905 |
Preclinical Animal (cat.) | Rat |
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | faricimab (Vabysmo, RG7716, faricimab-svoa) Roche / Genentech·Ang-2 / VEGF-A 53 trials·t½ Ocular ~7.5 days; minimal systemic exposure by design |
|---|---|
Overview Program | Vabysmo (faricimab) |
Overview Company | Roche / Genentech |
Overview Modality | ANTIBODY |
Overview Target | Ang-2 / VEGF-A |
Overview Indication | Wet AMD, diabetic macular edema, macular edema following retinal vein occlusion |
Overview Phase | APPROVED |
Overview Status | APPROVED |
Overview Content status | Curated Core |
Overview Data Confidence | Data Confidence · High |
Overview Development Signal | Development Signal · Established |
Overview Approval status | FDA approved |
Positioning Key differentiator | Dual pathway blockade targets vascular instability, not just leakage, which is what supports extended intervals. |
Positioning Known limitation | Persistent fluid despite dual blockade; interval shortening in a subset of eyes. |
Positioning Development positioning | Primary challenger to Eylea/Eylea HD on injection interval. |
MoA Mechanism | Neutralizes VEGF-A to reduce neovascularization and permeability while blocking Ang-2 to restore Tie2 signaling and vascular stability, reducing inflammation-driven leakage. |
MoA Biomarker | OCT central subfield thickness, BCVA, presence of intraretinal fluid. |
PK/PD Half-life | Ocular ~7.5 days; minimal systemic exposure by design |
PK/PD Species | Human, primate, CST reduction, fluid-free intervals, BCVA change |
PK/PD Animal (cat.) | Human |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Rat |
Toxicology Major finding | Injection-procedure risks — endophthalmitis, retinal detachment, IOP elevation — plus intraocular inflammation. Conjunctival hemorrhage is the most common local event. |
Toxicology CRS | N/A |
Clinical Safety signal | Injection-procedure risks — endophthalmitis, retinal detachment, IOP elevation — plus intraocular inflammation. Conjunctival hemorrhage is the most common local event. |
Clinical Selected reported efficacy | 16.9% |
Clinical Result source | ClinicalTrials.gov NCT04740905 |
Clinical Program phase | APPROVED |
Clinical Trial activity | No active/completed counts |
Clinical Trial ref | NCT04740905 |
Preclinical Animal (cat.) | Rat |
추천 비교
추천 비교